

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A live adenovirus formulation comprising 0.25% to 0.6% (w/v) chlorobutanol.

2. (currently amended) A live adenovirus formulation of claim 1 wherein the formulation contains from a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation 0.4% to 0.6% (w/v).

3. (original) A live adenovirus formulation of claim 1 wherein the formulation further comprises at least one inhibitor of free radical oxidation.

4. (currently amended) A live adenovirus formulation of claim 3 wherein the formulation further contains from a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation 0.4% to 0.6% (w/v).

5. (original) A live adenovirus formulation of claim 3 wherein the inhibitor of free radical oxidation is selected from the group consisting of EDTA, ethanol, histidine, or combinations thereof.

6. (currently amended) A live adenovirus formulation of claim 5 wherein the formulation further contains from a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation 0.4% to 0.6% (w/v).

7. (original) A live adenovirus formulation of claim 5 wherein the formulation further comprises a buffer, a cryoprotectant, a salt, a divalent cation, and a non-ionic detergent.

8. (currently amended) A live adenovirus formulation of claim 7 wherein the formulation further contains from a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation 0.4% to 0.6% (w/v).

9. (original) A live adenovirus formulation of claim 1 with an adenovirus concentration in the range from about 1×10^7 vp/mL to about 1×10^{13} vp/mL and a total osmolarity in a range from about 200 mOs/L to about 800 mOs/L.
10. (currently amended) A live adenovirus formulation of claim 9 wherein the formulation further contains from ~~a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation~~ 0.4% to 0.6% (w/v).
- 11-19. (canceled)
21. (currently amended) A filled multi-dose vaccine vial comprising live adenovirus and 0.25% to 0.6% (w/v) chlorobutanol.
22. (currently amended) The multi-dose vaccine vial of claim 21 wherein the formulation contains from ~~a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation~~ 0.4% to 0.6% (w/v).
23. (original) The multi-dose vaccine vial of claim 21 wherein the formulation further comprises at least one inhibitor of free radical oxidation.
24. (currently amended) The multi-dose vaccine vial of claim 23 wherein the formulation further contains from ~~a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation~~ 0.4% to 0.6% (w/v).
25. (currently amended) The multi-dose vaccine vial of claim 23 wherein ~~an~~ the inhibitor of free radical oxidation is selected from the group consisting of EDTA, ethanol, histidine, or combinations thereof.
26. (currently amended) The multi-dose vaccine vial of claim 25 wherein the formulation further contains from ~~a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation~~ 0.4% to 0.6% (w/v).
27. (original) The multi-dose vaccine vial of claim 25 wherein the formulation further comprises a buffer, a cryoprotectant, a salt, a divalent cation, and a non-ionic detergent.

28. (currently amended) The multi-dose vaccine vial of claim 27 wherein the formulation further contains from ~~a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation~~ 0.4% to 0.6% (w/v).

29. (original) The multi-dose vaccine vial of claim 21 with an adenovirus concentration in the range from about 1×10^7 vp/mL to about 1×10^{13} vp/mL and a total osmolarity in a range from about 200 mOs/L to about 800 mOs/L.

30. (currently amended) The multi-dose vaccine vial of claim 29 wherein the formulation further contains from ~~a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation~~ 0.4% to 0.6% (w/v).[[.]]

31. (currently amended) A method of preserving a live adenovirus formulation which comprises adding chlorobutanol to the formulation to a concentration of 0.25% to 0.6% (w/v), such that addition of chlorobutanol maintains adequate antimicrobial effectiveness while maintaining stability of the adenovirus for at least one year when stored at 2-8°C.

32. (currently amended) The method of claim 31 wherein the formulation contains from ~~a lowest effective concentration of chlorobutanol up to the solubility limit of chlorobutanol for said formulation~~ 0.4% to 0.6% (w/v).

33-36. (canceled)